BR112022003557A2 - Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos - Google Patents

Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos

Info

Publication number
BR112022003557A2
BR112022003557A2 BR112022003557A BR112022003557A BR112022003557A2 BR 112022003557 A2 BR112022003557 A2 BR 112022003557A2 BR 112022003557 A BR112022003557 A BR 112022003557A BR 112022003557 A BR112022003557 A BR 112022003557A BR 112022003557 A2 BR112022003557 A2 BR 112022003557A2
Authority
BR
Brazil
Prior art keywords
isolate
obtaining
concentrate
cannabinoid concentrate
cannabinoid
Prior art date
Application number
BR112022003557A
Other languages
English (en)
Inventor
Deborha Decorti
Venturini del Greco Giovanni
Venturini Del Greco Lorenzo
Original Assignee
Herbolea Biotech S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herbolea Biotech S P A filed Critical Herbolea Biotech S P A
Publication of BR112022003557A2 publication Critical patent/BR112022003557A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
    • B01D3/10—Vacuum distillation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos. a invenção refere-se a um concentrado e isolado de canabinoides com alto teor das formas ácidas dos canabinoides, método de obter os mesmos e uso dos mesmos compreendendo fornecer um extrato lipídico usando i.a. parafina e submetê-la a destilação específica a vácuo.
BR112022003557A 2019-08-27 2019-08-27 Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos BR112022003557A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/072843 WO2021037343A1 (en) 2019-08-27 2019-08-27 Cannabinoid concentrate and isolate, method of obtaining the same and use thereof

Publications (1)

Publication Number Publication Date
BR112022003557A2 true BR112022003557A2 (pt) 2022-05-24

Family

ID=67999599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003557A BR112022003557A2 (pt) 2019-08-27 2019-08-27 Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos

Country Status (15)

Country Link
US (1) US20220401405A1 (pt)
EP (1) EP4022077A1 (pt)
CN (1) CN114761572B (pt)
AR (1) AR116672A1 (pt)
AU (1) AU2019463310A1 (pt)
BR (1) BR112022003557A2 (pt)
CA (1) CA3149047A1 (pt)
CO (1) CO2022003480A2 (pt)
EC (1) ECSP22018842A (pt)
IL (1) IL290751A (pt)
MX (1) MX2022002475A (pt)
PE (1) PE20221403A1 (pt)
UY (1) UY38385A (pt)
WO (1) WO2021037343A1 (pt)
ZA (1) ZA202203193B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4431169A1 (en) 2023-03-17 2024-09-18 Siegfried AG Method of purifying cannabinoid components from plant extracts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
JP2017501971A (ja) 2013-11-11 2017-01-19 ザ ワーク ショップ， エルエルシー 無溶媒加工、システムおよび方法
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2016004410A1 (en) 2014-07-02 2016-01-07 Cannavest Corp. Novel process for generating hemp oil with a high cannabidiol (cbd) content
MX2017005277A (es) * 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
UY36530A (es) * 2015-01-22 2016-08-31 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
ES2759568T3 (es) 2015-03-23 2020-05-11 Echo Pharmaceuticals Bv Aislado de cannabidiol de cáñamo industrial y uso del mismo en preparaciones farmacéuticas y/o cosméticas
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3150264A1 (de) * 2015-09-30 2017-04-05 Bionorica Ethics GmbH Vakuumdestillation zur anreicherung von cbd
IL248150B (en) * 2016-09-29 2018-05-31 Garti Nissim A method for selective extraction of cannabinoid from plant origin
MX2019008373A (es) 2017-01-14 2019-12-02 Herbolea Biotech S R L Extraccion basada en lipidos asistida por enzimas y estabilizacion de fito-cannabinoides y terpenos, y productos obtenidos de los mismos.
US10828341B2 (en) * 2017-04-18 2020-11-10 Jose Rivas Method for preparation of pharmacologically-relevant compounds from botanical sources
US11759724B2 (en) * 2017-04-18 2023-09-19 Jose Rivas Method and apparatus for preparation of pharmacologically-relevant compounds from botanical sources
US10888595B2 (en) * 2017-04-18 2021-01-12 Jose Rivas Apparatus for preparation of pharmacologically-relevant compounds from botanical sources
CN107095302A (zh) * 2017-05-09 2017-08-29 何宗迅 大麻素类混合物及其在食品工业中的应用
US10189762B1 (en) * 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
GB2564459B (en) 2017-07-12 2022-03-09 Gw Res Ltd Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
EP3461545A1 (de) * 2017-09-30 2019-04-03 Bionorica Ethics GmbH Kurzwegdestillation im vakuum zur anreicherung von naturstoffen

Also Published As

Publication number Publication date
ECSP22018842A (es) 2022-05-31
WO2021037343A1 (en) 2021-03-04
AR116672A1 (es) 2021-06-02
EP4022077A1 (en) 2022-07-06
CO2022003480A2 (es) 2022-05-31
CN114761572B (zh) 2024-07-12
CA3149047A1 (en) 2021-03-04
CN114761572A (zh) 2022-07-15
UY38385A (es) 2021-01-29
ZA202203193B (en) 2023-09-27
US20220401405A1 (en) 2022-12-22
IL290751A (en) 2022-07-01
PE20221403A1 (es) 2022-09-15
AU2019463310A1 (en) 2022-04-07
MX2022002475A (es) 2022-03-22

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020002342A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada
CL2016001127A1 (es) Cepas de penicillium antifúngicas, sus extrolitos fungicidas, y su uso.
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112017006884B8 (pt) Estator de turbomáquina de aeronave e turbomáquina de aeronave
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
NI202100063A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112017002005A2 (pt) tubo híbrido, e, estrutura s de assento de avião.
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
CO2021001057A2 (es) Composición y método para el ahorro de opioides
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
WO2017083729A3 (en) Fixatives and methods of use
BR112022003557A2 (pt) Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
CL2023001140A1 (es) Formulaciones de anticuerpos anti-pd-l1
UY39407A (es) Concentrado de cannabinoides libre de thc, método de obtención del mismo y su uso
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.